Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study
Autore:
De Luca, A; Giancola, ML; Ammassari, A; Grisetti, S; Cingolani, A; Larussa, D; Alba, L; Murri, R; Ippolito, G; Cauda, R; Monforte, AD; Antinori, A;
Indirizzi:
Univ Sacred Heart, Ist Clin Malattie Infett, Dept Clin Infect Dis, I-00168Rome, Italy Univ Sacred Heart Rome Italy I-00168 Clin Infect Dis, I-00168Rome, Italy Natl Inst Infect Dis Lazzaro Spallanzani, IRCCS, Rome, Italy Natl Inst Infect Dis Lazzaro Spallanzani Rome Italy IRCCS, Rome, Italy Univ Milan, L Sacco Hosp Vialba, Inst Infect & Trop Dis, Milan, Italy UnivMilan Milan Italy osp Vialba, Inst Infect & Trop Dis, Milan, Italy
Titolo Testata:
JOURNAL OF NEUROVIROLOGY
fascicolo: 4, volume: 7, anno: 2001,
pagine: 364 - 368
SICI:
1355-0284(200108)7:4<364:PATWOW>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVE ANTIRETROVIRAL THERAPY; JC VIRUS LOAD; CEREBROSPINAL-FLUID; SURVIVAL; ERA; HAART; DNA;
Keywords:
PML; brain; opportunistic infections; viral infections; anti-retroviral therapy; anti-viral therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: De Luca, A Univ Sacred Heart, Ist Clin Malattie Infett, Dept Clin Infect Dis, Largo FVito 1, I-00168 Rome, Italy Univ Sacred Heart Largo F Vito 1 Rome Italy I-00168 ome, Italy
Citazione:
A. De Luca et al., "Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study", J NEUROVIRO, 7(4), 2001, pp. 364-368

Abstract

To analyze the clinical efficacy of cidofovir combined with highly active antiretroviral therapy (HAART) in AIDS-related progressive multifocal leukoen-cepalopathy (PML), a multicenter observational study was performed. Consecutive HIV-positive patients with histologically or virologically proven PML and at least 4 weeks of treatment after diagnosis were examined: 27 patients were treated with HAART, whereas 16 patients were treated with HAART plus cidofovir 5 mg/kg intravenously per week for the first 2 weeks and every other week thereafter. JC virus DNA was quantified in cerebrospinal fluid(CSF) by PCR. Baseline virologic, immunologic, and clinical characteristics as well as HIV RNA and CD4 responses to HAART were homogeneous between the groups. The median follow-up was 132 weeks. In one case (6%), cidofovir was permanently discontinued because of severe proteinuria. One-year cumulative probability of survival was 0.61 with cidofovir and 0.29 without (log rank test P = 0.02). After adjusting for baseline CD4 counts, JC viral load in CSF, Karnofsky, and use of HAART prior to the onset of PML, the use of cidofovir was independently associated with a reduced risk of death (hazard ratio, 0.21, 95% confidence interval, 0.07-0.65; P = 0.005). A randomized study will definitively establish whether cidofovir confers significant advantage over HAART alone in AIDS-related PML.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 09:45:19